21 results on '"Karsten Ridwelski"'
Search Results
2. Diagnostik und Therapie von Lebermetastasen bei kolorektalem Primärtumor
- Author
-
Jörg T. Hartmann, Hans J. Schlitt, Ernst J. Rummeny, Thomas Kirchner, Karsten Ridwelski, Helmut Oettle, Peter Neuhaus, Hauke Lang, Dirk Arnold, Markus Moehler, and Arnulf H. Hölscher
- Subjects
Gynecology ,Cancer Research ,medicine.medical_specialty ,Oncology ,business.industry ,Neoadjuvante Therapie ,KolorektalesKarzinom ,Lebermetastasen-Resektion ,MSCT ,DWI-MRT ,AdjuvanteTherapie ,Radiofrequenz-Ablation ,Medicine ,Hematology ,General Medicine ,business ,ddc - Abstract
Die kontrastverstärkte Mehrschicht-Computertomographie (MSCT) hat sich als das Standard-Schnittbildverfahren sowohl zur Diagnostik als auch zur Therapiekontrolle von Leberläsionen durchgesetzt. Zur Abklärung der lokalen Verhältnisse vor einer Leberteilresektion kann die diffusionsgewichtete Magnetresonanztomographie (DWI-MRT) wichtige zusätzliche Befunde liefern. Um das Kriterium der R0-Resektion zu erfüllen, erscheint ein Sicherheitsabstand von 0,5 mm ausreichend. Eine neoadjuvante Chemotherapie mit dem Ziel, die Tumorgröße zu verringern, kann parallel zur Pfortaderembolisation durchgeführt werden, ohne dass die perioperative Morbidität und Mortalität beeinträchtigt wird. Bezüglich des Managements primär resektabler Lebermetastasen besteht dringender Studienbedarf. Trotz der eher geringen Evidenz wird die adjuvante Chemotherapie in Deutschland derzeit breiter befürwortet als die perioperative Chemotherapie. Auch bezüglich der präoperativen Therapie bei Patienten mit (noch) nicht resektablen Lebermetastasen besteht erheblicher Studienbedarf. Bei KRAS-Wildtyp-Tumoren werden mit einer Cetuximab/Chemotherapie-Kombination hohe Ansprechraten (im Sinne einer metrischen Verkleinerung der Metastasen) erzielt. Bevacizumab/Chemotherapie-Kombinationen führen zu hohen pathohistologischen Komplett- und Partialremissionen. Welches der beste Parameter zur Erfolgsbeurteilung einer präoperativen Therapie ist, ist derzeit noch unbekannt, weshalb Vergleichsstudien mit dem Überleben als hartem Endpunkt durchgeführt werden müssen.
- Published
- 2009
3. Therapie des Magenkarzinoms
- Author
-
Florian Lordick, Pompiliu Piso, Tanja Trarbach, Salah-Eddin Al-Batran, Peter M. Schlag, and Karsten Ridwelski
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Cetuximab ,business.industry ,Hematology ,General Medicine ,Perioperative ,Oxaliplatin ,Clinical trial ,Capecitabine ,Docetaxel ,Internal medicine ,medicine ,Panitumumab ,business ,Epirubicin ,medicine.drug - Abstract
Even though adjuvant systemic therapy significantly increases 5-year survival rates for resectable gastric or gastroesophageal carcinoma, quality assurance research has shown that in practice it is often not given. The European standard, perioperative chemotherapy, is based on results of the MAGIC trial (3 cycles of ECF - epirubicin, cisplatin, 5-FU as infusion before and after surgery). It is to be expected that oral capecitabine will replace infusional 5-FU in perioperative treatment, as in the palliative setting. This change has already taken place in many institutions. For metastatic and locally advanced esophageal and gastric carcinoma, the results of clinical trials over recent years have led to the following concrete changes: the importance of platinum has been confirmed. Oxaliplatin can replace cisplatin. Capecitabine can replace 5-FU. If docetaxel is given in addition to platinum/5-FU, this doubles 2-year survival (with significant toxicity). Targeted drugs such as cetuximab, panitumumab, and bevacizumab are currently undergoing clinical trials.
- Published
- 2008
4. Therapie primär nichtresektabler Lebermetastasen
- Author
-
Ludger Staib, Pompiliu Piso, Andrea Tannapfel, Anke Reinacher-Schick, Meinolf Karthaus, Markus Moehler, Hans-Jürgen Schlitt, Wolfram T. Knoefel, Michael Kneba, Dirk Arnold, and Karsten Ridwelski
- Subjects
Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Bevacizumab ,Cetuximab ,business.industry ,medicine.medical_treatment ,Combination chemotherapy ,Hematology ,General Medicine ,Perioperative ,medicine.disease ,Surgery ,Metastasis ,Oncology ,Intensive therapy ,Medicine ,Embolization ,business ,medicine.drug - Abstract
A standardized procedure for dealing with nonresectable liver metastases does not currently exist. It is important that an interdisciplinary approach to treatment be taken, in order to look for the optimum solution for each individual patient. High response rates appear to be important, in order to make more patients with nonresectable liver metastases 'resectable' and thus provide a chance of cure. A series of randomized phase II-III trials found a clear increase in response rates and an improvement in the R0 resection rate as a result of more intensive therapy (triple chemotherapy or combination chemotherapy plus cetuximab or bevacizumab). In the NO16966 trial, too, under blinded conditions, more liver metastasis resections were carried out among patients who had received bevacizumab than among patients in the control arm without bevacizumab, although the response rates in the two arms were the same. A gap of 6-8 weeks between the last dose of bevacizumab and surgery is clinically optimal from the point of view of perioperative safety. If neoadjuvant treatment is given, then resection should be carried out as soon as the metastases are resectable. If the patient's response is not adequate, then consideration should be given to an adaptation or change of the treatment regimen. Regular evaluation for secondary resectability is important. Surgically, in addition to 2- or multi-stage surgery, other possible techniques include portal embolization and intraoperative ablation. The goal remains R0 resection. In order to minimize complications, clinicians must select patients carefully, take account of comorbidities, and know the critical resection volume.
- Published
- 2008
5. Adjuvante Therapie des Kolonkarzinoms
- Author
-
Karsten Ridwelski, Ulrich Hacker, Stefan Kubicka, Anke Reinacher-Schick, and Tanja Trarbach
- Subjects
Gynecology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Hematology ,General Medicine ,Oxaliplatin ,Oncology ,Older patients ,FOLFOX ,Capecitabin ,Medicine ,business ,medicine.drug - Abstract
Das Kolonkarzinom gehort zu den haufigsten Tumorentitaten und wird bei der Mehrheit der Patienten im lokalisierten Stadium diagnostiziert. Das Rezidivrisiko schwankt je nach Stadium zwischen 10 und 80%, kann aber bei Risikopatienten mit einer postoperativen Chemotherapie in relevantem Mase gesenkt werden. Im Stadium III ist die adjuvante Chemotherapie eindeutig indiziert, sofern keine Kontraindikationen vorliegen. Im Stadium II hat die Chemotherapie einen nur marginalen Effekt auf das rezidivfreie Uberleben und wird daher nicht routinemasig empfohlen. Bei Vorliegen von Risikofaktoren wie Perforation, unzureichender Anzahl untersuchter Lymphknoten etc. kann die Chemotherapie jedoch auch im Stadium II eine relevante Verbesserung bringen und sollte individuell mit den Patienten diskutiert werden. Es wird die Kombination aus Oxaliplatin plus 5-FU/Folinsaure (FOLFOX) empfohlen. Alternativ konnen auch orale Fluoropyrimidine als Monotherapie gegeben werden.
- Published
- 2008
6. Operative und perioperative Therapie von Lebermetastasen
- Author
-
Dirk Arnold, Anke Reinacher-Schick, Karsten Ridwelski, Hans J. Schlitt, Andrea Tannapfel, Markus Moehler, and Wolfram T. Knoefel
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Abstract
Das multimodale Management sowie innovative chirurgische Techniken haben die Therapie und Prognose von Patienten mit Lebermetastasen vollig verandert und deutlich verbessert. Ob Patienten mit resektablen Lebermetastasen eine neoadjuvante und/oder adjuvante Chemotherapie erhalten sollten, wird derzeit noch kontrovers diskutiert. Ist eine R0-Resektion moglich (primar oder nach Vorbehandlung), sollte diese aus chirurgischer Sicht ohne Verzogerung erfolgen. Eine limitierte Resektion (Subsegment/Segment/nichtanatomische Resektion) ist adaquat, wenn die Metastasen komplett entfernt werden konnen, und hat den Vorteil des Erhalts von mehr funktionalem Lebergewebe, um im Fall eines Rezidivs eine Zweit-und eventuell Drittresektion vornehmen zu konnen. Ein geringer Sicherheitsabstand (
- Published
- 2008
7. Contents Vol. 53, 2007
- Author
-
Pan Wang, Yuichi Tanaka, Sebastian G. B. Amyes, J. Fahlke, George Dimitracopoulos, Quanhong Liu, Frank Meyer, Hidetsugu Nakayama, Chieko Murayama, Maja A. Hofmann, Iris Spiliopoulou, Yoichi Tanaka, Matthias Pross, G. Royo, Uwe Trefzer, K. Ridwelski, Hiroya Takami, H. Lippert, Myrto Christofidou, Regine Schneider-Stock, Seiei Yasuda, Arndt Hribaschek, Lina Xiao, Karsten Ridwelski, Yoshikazu Gotoh, Sofia Zografou, Kenji Ishikawa, Hiroko Sasahara, Wolfram Sterry, Hussien O. AlKadi, I. Escribano, Akemi Kamijo, Susumu Sueyoshi, Toshiaki Tanaka, Verena Gabriel, B. Llorca, J.C. Rodríguez, F. Garcia e Costa, Naoki Mori, T. Deist, T. Nagano, Fiona Walsh, Sotaro Sadahiro, Xiaobing Wang, Phil Turner, Kazuo Shirouzu, Annett Milling, Hiromasa Fujita, U. Keilholz, M. Assmann, Hans Lippert, D. Quietzsch, Yuji Maeda, P. Stuebs, E. García-Pachon, Rajesh Pandey, Gopal K. Khuller, Shinichiro Akiyama, Zerrin Yulugkural, M.L. Pereira, Toshiyuki Suzuki, Simon Bracher, Felix Kiecker, K. Hribaschek, Haluk Vahaboglu, Sıla Akhan, C. Schmidt, M. Ruiz, Hiromichi Gotoh, Amalia Goula, Hideaki Yamana, E. Kettner, and Hiroyasu Makuuchi
- Subjects
Pharmacology ,Infectious Diseases ,Oncology ,Drug Discovery ,Pharmacology (medical) ,General Medicine - Published
- 2007
8. A Multicentre Phase II Study of Docetaxel plus Cisplatin for the Treatment of Advanced Gastric Cancer
- Author
-
Karsten Ridwelski, T. Deist, Patrick Stuebs, D. Quietzsch, Hans Lippert, K. Hribaschek, C. Schmidt, M. Assmann, J. Fahlke, U. Keilholz, and E. Kettner
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Phases of clinical research ,Docetaxel ,Stomach Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Drug Discovery ,Humans ,Medicine ,Pharmacology (medical) ,Prospective Studies ,Prospective cohort study ,Survival rate ,Peritoneal Neoplasms ,Aged ,Ovarian Neoplasms ,Pharmacology ,Cisplatin ,Chemotherapy ,business.industry ,Liver Neoplasms ,digestive, oral, and skin physiology ,General Medicine ,Middle Aged ,digestive system diseases ,Survival Rate ,Clinical trial ,Regimen ,Treatment Outcome ,Infectious Diseases ,Lymphatic Metastasis ,Female ,Taxoids ,Neoplasm Recurrence, Local ,business ,medicine.drug - Abstract
Background: The optimum regimen for advanced gastric cancer requires definition. This multicentre phase II study evaluated docetaxel-cisplatin combination in advanced gastric cancer. Methods: Chemotherapy-naïve patients with locally advanced or metastatic disease received docetaxel plus cisplatin (75/75 mg/m2) every 21 days for up to 9 cycles. Endpoints included tumour response, time to progression, overall survival and toxicity. Results: Of 113 patients recruited, 88 were completely evaluable. The median age was 58 years, and most patients had metastatic disease. The overall response rate was 29.6%. Five patients (5.7%) achieved a complete response and 21 patients (23.9%) had a partial response. Tumour control, including stable disease, was achieved in 57 patients (64.8%). The median time to progression and median overall survival time was 4.8 and 8.7 months, respectively. The major toxicity was haematological: 37.5% of patients experienced grade 3–4 neutropenia, whereas febrile neutropenia was observed in only 2% of patients. Conclusion: Docetaxel-cisplatin was active with a predictable and manageable toxicity profile.
- Published
- 2007
9. Pharmacokinetics of the Antineoplastic Drug Mitomycin C in Regional Chemotherapy Using the Aortic Stop Flow Technique in Advanced Pancreatic Carcinoma
- Author
-
Hans Lippert, Jens Martens-Lobenhoffer, T. Gebauer, Frank Meyer, Karsten Ridwelski, and Reinhard Grote
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pancreatic disease ,Mitomycin ,medicine.medical_treatment ,Urology ,Biological Availability ,Pharmacokinetics ,Drug Discovery ,medicine ,Humans ,Pharmacology (medical) ,Survival rate ,Peritoneal Neoplasms ,Aged ,Pharmacology ,Chemotherapy ,Antibiotics, Antineoplastic ,business.industry ,Liver Neoplasms ,Mitomycin C ,Area under the curve ,General Medicine ,Middle Aged ,medicine.disease ,Surgery ,Pancreatic Neoplasms ,Survival Rate ,Treatment Outcome ,Infectious Diseases ,Oncology ,Tumor progression ,Area Under Curve ,Chemotherapy, Cancer, Regional Perfusion ,Female ,business ,Perfusion - Abstract
Background: An isolated perfusion may lead to a higher concentration of cytostatics within the target tissue, which can be associated with a high response rate and longer survival in addition to a low rate of side effects in comparison with systemic palliative chemotherapy. The aim of the present study was to investigate the pharmacokinetics of mitomycin C utilizing the aortic stop flow technique with commercially available tools in patients with advanced pancreatic carcinoma. Methods: Seventeen patients with unresectable or metastasized pancreatic carcinoma (diagnosed by histological investigation) underwent a 20-min hypoxic perfusion of the isolated abdominal compartment with 20 mg/m2 mitomycin C (MitomedacTM, medac, Hamburg, Germany) 22 times. Cytostatic concentration was determined intrainterventionally within the systemic and regional compartment. Results: The mitomycin C concentration was 10 times higher within the regional compared with the systemic compartment at its maximum. The area under the curve was 4.02 times greater. Toxicity was considerable, i.e. WHO grade I/II in 8 of 17 cases, and III/IV in 9 of 17 cases. Two treatment-related deaths were documented. The objective response rate was 17.6% (3 of 17 cases; 1 complete remission, 2 partial remissions). In 3 subjects, stable disease was registered, and in 11 individuals, tumor progression. The median survival was 4.1 months. Conclusion: Though high concentrations of the cytostatic drug were achieved within the regional compartment, the aortic stop flow technique was associated with a high toxicity rate but no improvement of tumor response and survival in comparison with systemic chemotherapy. Despite its pharmacokinetic advantages, the aortic stop flow technique is currently not recommendable for routine use.
- Published
- 2005
10. Phase I Trial Using Weekly Administration of Gemcitabine and Docetaxel in Patients with Advanced Pancreatic Carcinoma
- Author
-
A. Lueck, A. Hribaschek, Karsten Ridwelski, Hans Lippert, and Frank Meyer
- Subjects
Male ,Oncology ,Antimetabolites, Antineoplastic ,medicine.medical_specialty ,Pancreatic disease ,medicine.drug_class ,Health Status ,medicine.medical_treatment ,Docetaxel ,Deoxycytidine ,Severity of Illness Index ,Antimetabolite ,Drug Administration Schedule ,Metastasis ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Drug Discovery ,medicine ,Humans ,Pharmacology (medical) ,In patient ,Pancreatic carcinoma ,Neoplasm Metastasis ,Aged ,Pain Measurement ,Pharmacology ,Chemotherapy ,Dose-Response Relationship, Drug ,business.industry ,Carcinoma ,General Medicine ,Middle Aged ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Gemcitabine ,Pancreatic Neoplasms ,Infectious Diseases ,Quality of Life ,Female ,Taxoids ,business ,medicine.drug - Abstract
Background: In advanced pancreatic carcinoma, no effective chemotherapy has been found yet due to the lack of appropriate response. The frequent use of gemcitabine is based on the fact that there is a significant improvement in the quality of life, but neither an effect on remission nor a detectable increase in survival rates could be observed. Therefore, the hypothesis was that the combination of gemcitabine with other drugs can result in a better outcome of patients. The aim of this study was to determine the maximally tolerable dosage of gemcitabine and docetaxel using a weekly administration regimen. Patients and Methods: Twenty-five patients with advanced or metastatic pancreatic carcinoma received combination chemotherapy using gemcitabine and docetaxel in a weekly administration regimen, beginning with 800 mg/m2 of gemcitabine and 25 mg/m2 of docetaxel. Four patients were originally enrolled for each of the seven different dosages of both drugs. Side effects were assessed according to the WHO standard. Quality of life was evaluated according to the Core Quality of Life Questionnaire (QLQ-C30) of the European Organization for Research and Treatment of Cancer. Results: Using the two maximal dosages of gemcitabine and docetaxel (gemcitabine, 800 and 1,000 mg/m2, and docetaxel, 45 and 40 mg/m2; respectively), only 3 and 2 patients were enrolled, respectively, because of toxic side effects ≧ grade III according to WHO grading. Maximal dosages with tolerable side effects were 1,000 mg/m2 of gemcitabine and 35 mg/m2 of docetaxel given in weekly intervals. Main side effects of this combination chemotherapy were gastrointestinal symptoms and hematologic toxicity. Conclusion: Combination therapy with gemcitabine and docetaxel in advanced or metastatic pancreatic carcinoma is a well-tolerated and acceptable alternative treatment option with regard to the severity of side effects and its positive impact on quality of life and tumor-associated pain. According to the study endpoint, dosages of 1,000 mg/m2 of gemcitabine and 35 mg/m2 of docetaxel are recommended as maximum-tolerated doses (given in weekly intervals) for a future phase II trial.
- Published
- 2004
11. Current Options for Palliative Treatment in Patients with Pancreatic Cancer
- Author
-
Karsten Ridwelski and Frank Meyer
- Subjects
Oncology ,Antimetabolites, Antineoplastic ,medicine.medical_specialty ,Palliative care ,Combination therapy ,medicine.medical_treatment ,Deoxycytidine ,Internal medicine ,Pancreatic cancer ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Exocrine pancreatic insufficiency ,Chemotherapy ,business.industry ,Carcinoma ,Palliative Care ,Gastroenterology ,General Medicine ,Prognosis ,medicine.disease ,Survival Analysis ,Gemcitabine ,Pancreatic Neoplasms ,Radiation therapy ,Docetaxel ,Quality of Life ,business ,medicine.drug - Abstract
Palliative treatment is often the only remaining option in the management of pancreatic carcinoma, but its efficacy is poor due to low tumor sensitivity and inadequate treatment protocols. There are several options of palliative treatment with antitumor or supportive intention. Classical end points of palliative treatment are survival, tumor response, and quality of life. A decade ago, palliative chemotherapy consisted mainly of 5-fluorouracil as the standard agent in combination with either other agents and/or radiotherapy. Only the new antineoplastic drug gemcitabine, which was introduced simultaneously with the definition of novel end points of chemotherapy such as clinical benefit, allowed to achieve some progress. However, while gemcitabine monotherapy appeared to be superior to 5-fluorouracil and improved important parameters of quality of life, it could not provide a significant improvement of survival. A novel concept, therefore, is to improve this beneficial cytostatic response in pancreatic carcinoma using a gemcitabine-based protocol by combining it with antineoplastic drugs such as taxanes or platin analogs. This strategy may have the potential to improve the outcome in palliative chemotherapy of pancreatic carcinoma patients with advanced tumor growth or metastases. Best supportive care in pancreatic cancer consists of the treatment of symptoms, such as pain, jaundice, duodenal obstruction, weight loss, exocrine pancreatic insufficiency, and tumor-associated depression.
- Published
- 2001
12. Contents Vol. 50, 2004
- Author
-
György Szabó, Yoshikazu Ishii, Christos P. Flevaris, Satoshi Yoshizumi, A. Hribaschek, K. Charalabopoulos, Daisuke Kato, Zalán Szántó, Karsten Ridwelski, Takashi Niimi, A.J. Carrillo-Muñoz, Georgios A. Hartzoulakis, Ediz Demirpençe, L. Zoganas, Dimitrios C. Dandakis, Hande Canpinar, A. Lueck, Yoshinari Watanabe, Béla Kocsis, C. Guardia, A. Lale Doğan, Iris Karachaliou, Hans Lippert, Georgios Karachalios, Antonios K. Zacharof, J.B. Casals, Lehel Bálint, Guillermo Quindós, George D. Bablekos, A. Guglietta, Sotirios G. Kalogeropoulos, C. Palacín, Kazuhiro Tateda, Övünç Düzgünçınar, O. del Valle, George N. Karahalios, Vilmarie Rodriguez, Ryuzo Ueda, Eiichi Okezaki, Frank Meyer, Hiroyoshi Maeda, Tetsuya Oguri, Hiroyuki Achiwa, Alexander Charalabopoulos, Shigeki Sato, Yoshie Takahashi, Constantinos L. Petrogiannopoulos, and Ayça Doğan
- Subjects
Pharmacology ,Infectious Diseases ,Oncology ,Drug Discovery ,Pharmacology (medical) ,General Medicine - Published
- 2004
13. A Multicenter Prospective Randomized Trial with Assessment of Quality of Life in Patients with Metastatic Colorectal Carcinoma Comparing Interferon α-2b and Folinic Acid as Modulators of 5-Fluorouracil
- Author
-
J. Reichert, T. Zwingers, R.U. Hilgenfeld, D. Zillig, H.W. Dreyer, R. Pasold, Karsten Ridwelski, P.M. Ehrich, T. Küchler, Stefan Schwartz, W. Abenhardt, E.D. Kreuser, J.B. Boese-L·andgraf, M. Kairies, L. Reichel, P. David, Ch. Boewer, W. Stein, S.K. Jakob, Wolfgang E. Berdel, Eckhard Thiel, F. Bach, M. Matthias, and R. Böthig
- Subjects
Oncology ,Cancer Research ,Chemotherapy ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,medicine.medical_treatment ,Hematology ,medicine.disease ,law.invention ,Folinic acid ,Quality of life ,Randomized controlled trial ,Interferon ,Fluorouracil ,law ,Internal medicine ,medicine ,In patient ,business ,medicine.drug - Abstract
Background : The biochemical rationale for the use of folinic acid (FA) and interferon (IFN) to modulate and thereby enhance the antitumor activity of 5-fluorouracil (5-FU) in vitro
- Published
- 1994
14. Liver Abscess as a First Manifestation of Crohn’s Disease
- Author
-
Jörg Pertschy, Helmut Wolff, Karsten Ridwelski, Klaus Gellert, Meinhard Lüning, and Tahar Benhidjeb
- Subjects
medicine.medical_specialty ,education.field_of_study ,Crohn's disease ,business.industry ,Crohn disease ,Incidence (epidemiology) ,Population ,Gastroenterology ,Disease ,medicine.disease ,Internal medicine ,Medicine ,Surgery ,business ,Complication ,Abscess ,education ,Liver abscess - Abstract
Although for patients with Crohn’s disease a significantly higher incidence of liver abscesses has been theoretically calculated than for patients of the general population, there are only 30 cases re
- Published
- 1992
15. Carcinoma Arising in a Choledochal Cyst 23 Years after Choledochocystojejunostomy
- Author
-
Klaus Gellert, Karsten Ridwelski, Bozena Münster, Tahar Benhidjeb, and Helmut Wolff
- Subjects
medicine.medical_specialty ,Enteric drainage ,business.industry ,Gastroenterology ,medicine.disease ,Complete resection ,Surgery ,Surgical anastomosis ,medicine ,Carcinoma ,Adenocarcinoma ,Choledochal cysts ,Cyst ,business ,Biliary tract disease - Abstract
A case of adenocarcinoma arising in a choledochal cyst (type I in the Todani classification) 23 years after enteric drainage is presented. A complete resection of the choledochal duct with the choledo
- Published
- 1992
16. Subject Index Vol. 53, 2007
- Author
-
A. Hribaschek, Toshiyuki Suzuki, Karsten Ridwelski, Hiroya Takami, Yoshikazu Gotoh, Yuichi Tanaka, Susumu Sueyoshi, Pan Wang, J.C. Rodríguez, J. Fahlke, Quanhong Liu, Frank Meyer, Zerrin Yulugkural, G. Royo, Hiroyasu Makuuchi, Fiona Walsh, Iris Spiliopoulou, H. Lippert, Sotaro Sadahiro, Matthias Pross, Seiei Yasuda, Sofia Zografou, Hiroko Sasahara, Sebastian G. B. Amyes, T. Deist, George Dimitracopoulos, Regine Schneider-Stock, Simon Bracher, Toshiaki Tanaka, Hussien O. AlKadi, Maja A. Hofmann, E. García-Pachon, Chieko Murayama, Naoki Mori, Felix Kiecker, Lina Xiao, T. Nagano, I. Escribano, Xiaobing Wang, Phil Turner, B. Llorca, Akemi Kamijo, Uwe Trefzer, Myrto Christofidou, Kenji Ishikawa, Wolfram Sterry, Hans Lippert, C. Schmidt, M. Ruiz, K. Ridwelski, Hiromichi Gotoh, Verena Gabriel, Yuji Maeda, Amalia Goula, Hideaki Yamana, E. Kettner, K. Hribaschek, Haluk Vahaboglu, D. Quietzsch, P. Stuebs, Annett Milling, Rajesh Pandey, Gopal K. Khuller, Shinichiro Akiyama, M.L. Pereira, M. Assmann, Yoichi Tanaka, Sıla Akhan, Hidetsugu Nakayama, Kazuo Shirouzu, Hiromasa Fujita, U. Keilholz, and F. Garcia e Costa
- Subjects
Pharmacology ,Infectious Diseases ,Index (economics) ,Oncology ,Drug Discovery ,Statistics ,Pharmacology (medical) ,Subject (documents) ,General Medicine ,Mathematics - Published
- 2007
17. Subject Index Vol. 50, 2004
- Author
-
Eiichi Okezaki, Frank Meyer, Daisuke Kato, Hande Canpinar, Satoshi Yoshizumi, C. Palacín, György Szabó, Zalán Szántó, Guillermo Quindós, Takashi Niimi, Alexander Charalabopoulos, Yoshinari Watanabe, Karsten Ridwelski, Béla Kocsis, Shigeki Sato, K. Charalabopoulos, A. Lueck, Ediz Demirpençe, L. Zoganas, Dimitrios C. Dandakis, Övünç Düzgünçınar, Georgios Karachalios, C. Guardia, A. Lale Doğan, Yoshikazu Ishii, A. Hribaschek, Sotirios G. Kalogeropoulos, A. Guglietta, Constantinos L. Petrogiannopoulos, Ayça Doğan, Yoshie Takahashi, O. del Valle, Antonios K. Zacharof, George N. Karahalios, Kazuhiro Tateda, Vilmarie Rodriguez, Ryuzo Ueda, Christos P. Flevaris, Georgios A. Hartzoulakis, Hiroyoshi Maeda, Iris Karachaliou, Hans Lippert, Tetsuya Oguri, Hiroyuki Achiwa, George D. Bablekos, A.J. Carrillo-Muñoz, J.B. Casals, and Lehel Bálint
- Subjects
Pharmacology ,medicine.medical_specialty ,Index (economics) ,business.industry ,Subject (documents) ,General Medicine ,medicine.disease_cause ,Virology ,Cefcapene ,Haemophilus influenzae ,Infectious Diseases ,Oncology ,Levofloxacin ,Internal medicine ,Drug Discovery ,Medicine ,Pharmacology (medical) ,business ,medicine.drug - Published
- 2004
18. CXCR4-Antagonist: Plerixafor verbessert die Mobilisierung in der autologen hämatopoetischen Stammzelltransplantation
- Author
-
Grit Mehlhorn, Zhen Chen, Cornelius F. Waller, Hana Ciferská, Salah-Eddin Al-Batran, Martin Fehr, Lucie Kalinová, Sebastian Fetscher, Bertrand Coiffier, Karsten Ridwelski, Wu Ni, Nadine Lukan, Xiang-Yang Jiang, Beibei Zhang, Michael Stamatakos, Karel Krejčí, Rodeina Challand, Matthias Birth, Josef Srovnal, Kun Wang, Charikleia Stefanaki, Radek Trojanec, Klaus Wehle, Michaela Zezulová, Dmitry Bentsion, Laura Kahmann, Vratislav Strnad, Wen-Kang Liu, Jian-Kang Ren, Richard Cathomas, Konstantinos Kontzoglou, Lei Wang, Peter A. Fasching, Stavroula Masouridi, Florian Lordick, Pavel Horák, Miloslava Zlevorová, Tomáš Tichý, Ralf-Dieter Hofheinz, Junxue Wang, Zhen-Xi Zhang, Marian Hajduch, M. Furrer, Michael Safioleas, Ulrich Beyer, Vladimir Semiglazov, Falk Thiel, Stephen L. Chan, Harald Scheiber, George H. Sakorafas, Roger von Moos, Josef Zadražil, Wensheng Xu, Sergei Tjulandin, Christian Görg, and Michael P. Lux
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Published
- 2010
19. Population-Based Patterns of Care in the First-Line Treatment of Patients with Advanced Esophagogastric Adenocarcinoma in Germany
- Author
-
Karsten Ridwelski, Christian Görg, Matthias Birth, Harald Scheiber, Florian Lordick, Sebastian Fetscher, Nadine Lukan, Klaus Wehle, Salah-Eddin Al-Batran, and Ralf-Dieter Hofheinz
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Esophageal Neoplasms ,medicine.medical_treatment ,Population ,Comorbidity ,Adenocarcinoma ,Capecitabine ,Stomach Neoplasms ,Germany ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Practice Patterns, Physicians' ,education ,Aged ,Cisplatin ,Chemotherapy ,education.field_of_study ,business.industry ,Incidence ,Cancer ,Hematology ,General Medicine ,medicine.disease ,Oxaliplatin ,Irinotecan ,Treatment Outcome ,Docetaxel ,Female ,business ,medicine.drug - Abstract
Randomized studies proved the efficacy of new drugs for the systemic treatment of advanced gastric cancer in the past 5 years. However, little is known about the use of firstline chemotherapy in clinical practice in patients with advanced or metastatic adenocarcinoma of the esophagogastric junction (AEG) and the stomach. We investigated temporal trends in therapy and factors influencing treatment decisions for these patients during a 4-year period.1058 patients (median age 67 years) with advanced AEG or gastric cancers undergoing treatment decisions were documented with the Therapiemonitor® in 2006-2009. Therapiemonitor collects population-based data regarding treatment decisions and strategies. Time trends of drug use and intensity in the first-line treatment were analyzed in the entire patient group and according to age (cut-off 65 years) and Karnofsky performance status (KPS; cut-off 80%).Over time, the use of oxaliplatin and docetaxel as well as capecitabine increased while cisplatin and irinotecan use slightly declined. The use of chemotherapy triplets rose from 10.1% in 2006 to 47.0% in 2009. Treatment patterns significantly varied by age and KPS: Older patients were significantly less likely to receive chemotherapy triplets, cisplatin and docetaxel but tended to more often receive oxaliplatin. Likewise, triplets, cisplatin and docetaxel were less frequently used in patients with KPS80%, while capecitabine and irinotecan were significantly more often used in this patient group.A clear tendency towards the use of more intensive chemotherapy regimens in patients with AEG and gastric cancer was observed over time. Older or less fit patients were treated preferably with monotherapy or chemotherapy doublets during 2006-2009. Oxaliplatin and docetaxel use has substantially risen.
- Published
- 2010
20. T-DM1 ± Pertuzumab als First-line-Option in der Phase-III-Prüfung: MARIANNE-Studie beim HER2-positiven Mammakarzinom
- Author
-
Radek Trojanec, Josef Srovnal, Kun Wang, Christian Görg, Michael P. Lux, Stephen L. Chan, Michaela Zezulová, Rodeina Challand, Grit Mehlhorn, Peter A. Fasching, Jian-Kang Ren, Michael Stamatakos, Cornelius F. Waller, Martin Fehr, Hana Ciferská, Vratislav Strnad, George H. Sakorafas, Nadine Lukan, Zhen Chen, Josef Zadražil, Lucie Kalinová, Sebastian Fetscher, Ralf-Dieter Hofheinz, Miloslava Zlevorová, Zhen-Xi Zhang, Salah-Eddin Al-Batran, M. Furrer, Vladimir Semiglazov, Matthias Birth, Dmitry Bentsion, Falk Thiel, Karel Krejčí, Richard Cathomas, Wensheng Xu, Marian Hajduch, Lei Wang, Charikleia Stefanaki, Sergei Tjulandin, Stavroula Masouridi, Tomáš Tichý, Wen-Kang Liu, Laura Kahmann, Pavel Horák, Beibei Zhang, Michael Safioleas, Bertrand Coiffier, Wu Ni, Ulrich Beyer, Klaus Wehle, Karsten Ridwelski, Xiang-Yang Jiang, Florian Lordick, Roger von Moos, Konstantinos Kontzoglou, Harald Scheiber, and Junxue Wang
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Published
- 2010
21. VIII. Interdisziplinärer Expertenworkshop 2008 ‘Gastrointestinale Tumore’ – Autorenverzeichnis
- Author
-
Hans J. Schlitt, Meinolf Karthaus, Thomas Höhler, Hans-Joachim Schmoll, Karsten Ridwelski, Pompiliu Piso, Andrea Tannapfel, Florian Lordick, Markus Moehler, Hans-Jürgen Schlitt, Rolf Sauer, Dirk Arnold, Wolfram T. Knoefel, Michael Kneba, Michael Flentje, Peter M. Schlag, Volker Budach, Helmut Oettle, Anke Reinacher-Schick, Ludger Staib, René Siewczynski, Claus Rödel, Wolff Schmiegel, Ulrich Hacker, Salah-Eddin Al-Batran, Tanja Trarbach, and Stefan Kubicka
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.